Summary

Overview
Global Single Cell Omics Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Omics encompasses various molecular analyses, including genomics, transcriptomics, proteomics, lipidomics, and metabolomics. Transcriptomics analyzes gene expression patterns across whole tissues or organs. With emerging technologies in single-cell isolation and more sensitive molecular technologies, omics analyses can now be conducted at single-cell resolution, providing unique insights into the heterogeneity of cells across tissues.
Market Dynamics: Drivers and Restraints
Increasing demand for personalized medicines
Several factors are driving the growth of the single-cell omics market one of the major drivers is the increasing demand for personalized medicine. Analyzing individual cells at a molecular level can provide valuable insights into the underlying disease mechanisms, leading to more precise and customized treatments. Also, rapid technological advancements have made single-cell omics more accessible and cost-effective.
For instance, in June 2021, SCIENION and Cellenion announced the launch of the cellenCHIP 384 for single-cell omics sample preparation, introducing it as the integral consumable in the new cellenCHIP 384 – 3’RNA-seq Kit for scalable, nanoliter volume library preparation of single cells.
The cellenCHIP 384, with its nano well format, accessory range and options for customization, further extends the automated capabilities of the cellenONE for miniaturization and high throughput workflows. Single-cell omics lead to life-changing advances in precision medicine and the technologies greatly enhance analyte profiling possibilities in fields such as oncology.
Furthermore, an increase in various initiatives and collaborations among pharmaceutical and biotechnological companies and research institutes play a pivotal role and thus, further boost the market growth.
Market Dynamics: Restraint
Safety concerns are one of the restraint factors that hamper the market growth during the forecast period. The use of single-cell omics technologies raises ethical concerns related to privacy, informed consent, and the potential misuse of data. These issues need to be addressed to ensure responsible use and ethical practices in the field.
Segment Analysis
The global single-cell omics market is segmented based on product type, application, end-user and region.
The single-cell genomics from the product type segment accounted for approximately 41.5% of the single-cell omics market share
The single cell genomics from the product type segment accounted for approximately 41.5% and it is expected to be dominated during the forecast period. Single-cell genomics is the study of the individuality of cells using omics approaches. Although young, the field has now entered its teenage years and is beginning to show clear signs of maturity. Its origins can be traced back to pioneering experiments that allowed the detection of gene expression in single cells by microarrays.
Factors such as increasing demand from a wide range of end-users, potential clinical applications of single-cell genomics platforms, and technological advancements are the major factors driving segment growth.
For instance, in January 2023, the Genome Sciences core facility stated that leading-edge technologies, including single-cell multiomics and spatial transcriptomics, are now available. For single-cell genomics using the 10x Genomics Chromium controller, up to 10,000 cells can be captured in a single sample. For spatial transcriptomics, Visium spatial gene expression services are offered both in formalin-fixed paraffin-embedded (FFPE) and fresh frozen tissues.
Moreover, in March 2022, Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, launched the first-in-class single-cell genomics solid tumor solution on the tapestri platform for solid tumor research. This new end-to-end single-cell DNA sequencing workflow on the Tapestri Platform includes nuclei isolation prep protocol, pre-designed research panels for breast cancer and glioblastoma multiforme, and an improved single-cell copy number variation (CNV) bioinformatic analysis tool.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the well-established research and development infrastructure, including top universities, research institutions, and pharmaceutical companies, companies’ expansion, ongoing research and development will further drive this region to have highest market share.
For instance, in August 2023, Scale Biosciences, Inc. an innovator in single-cell sequencing leveraging combinatorial indexing technologies, started an expansion of their product portfolio to enable a broader range of single-cell omics experiments and unlock new translational research applications.
Moreover, in December 2022, Scale Biosciences, Inc. (ScaleBio), a pioneer in single-cell sequencing and combinatorial indexing technologies, transitioned from research and development to the commercial stage with the release of its first generation single-cell transcriptomics scRNAseq profiling and analysis solution, establishing new standards for accessible, scalable, and low-cost single-cell sequencing.
COVID-19 Impact Analysis
COVID-19 had a positive impact on the market as this technology was in high demand to investigate the viral-host interactions, immune response, and the effects of the virus on various cell types. In addition, technology has been used in developing precision diagnostics by studying specific markers.
Market Segmentation
By Product Type
• Single-cell Genomics
• Single-cell Proteomics
• Single-cell Metabolomics
• Single-cell Transcriptomics
By Application
• Oncology
• Cell Biology
• Neurology
• Immunology
• Others
By End User
• Pharmaceutical & Biotechnology companies
• Academic and Research Organizations
• Hospitals and Diagnostic laboratories
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include CYTENA GmbH, 10x Genomics, Becton, Dickinson and Company, CELLENION, Bio-Rad Laboratories Inc, Mission Bio, Standard BioTools Inc, Nanostring, Takarabio, BGI Genomics Co and among others.
Key Developments
 In February 2023, Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, stated the launch of its Max Read Kits for single-cell applications on the company’s G4 Sequencing Platform at the Advances in Genome Biology and Technology (AGBT) 23rd General Meeting.
Why Purchase the Report?
• To visualize the global single-cell omics market segmentation based on product type, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of single-cell omics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global single-cell omics market report would provide approximately 61 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing demand for precision medicines
4.1.1.2. Rise in the prevalence of cancers
4.1.2. Restraints
4.1.2.1. Safety concerns
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Single-cell Genomics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Single-cell Proteomics
7.4. Single-cell Metabolomics
7.5. Single-cell Transcriptomics
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
8.2.1. Introduction
8.3. Cell biology
8.4. Neurology
8.5. Immunology
8.6. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Pharmaceutical & Biotechnology companies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Academic and Research Organizations
9.4. Hospitals and Diagnostic Laboratories
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.5.1. Germany
10.3.5.2. UK
10.3.5.3. France
10.3.5.4. Italy
10.3.5.5. Spain
10.3.5.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.5.1. Brazil
10.4.5.2. Argentina
10.4.5.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.4.1. China
10.5.4.2. India
10.5.4.3. Japan
10.5.4.4. Australia
10.5.4.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. CYTENA GmbH *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. 10x Genomics
12.3. Becton, Dickinson and Company
12.4. CELLENION
12.5. Bio-Rad Laboratories Inc
12.6. Mission Bio
12.7. Standard BioTools Inc
12.8. Nanostring
12.9. Takarabio
12.10. BGI Genomics Co
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us